FORT LAUDERDALE, FL., Feb. 11, 2022 (BUSINESS WIRE) — Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy announced today that Charles J. Link, M.D., Executive Chairman & Chief Medical Officer of Syncromune will deliver a presentation at the 2022 BIO CEO & Investor Conference. Taking place February 14 – 17, 2022 at the New York Marriot Marquis, the conference will feature a hybrid of virtual and in-person participation.
Dr. Link will be highlighting Syncromune’s recent corporate achievements, including the recent completion of the in-licensing of four target assets. He will also review the company’s proprietary Syncrovax™ platform, which is a next-generation personalized cancer therapy being developed to optimize intratumoral immunotherapy for the treatment of metastatic solid tumors.
Members of the company’s executive team will be on site for one-on-one meetings with investors and companies. A copy of the presentation will be available on Syncromune’s website following the conclusion of the BIO CEO & Investor Conference.
Syncromune is a privately held, clinical stage biopharmaceutical company dedicated to the development of novel intratumoral immunotherapies for solid tumors. Syncromune is committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax, a novel platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. The platform is designed to enable the patient’s immune system to recognize and attack cancer throughout the body. The pipeline includes nine potential indications with the possibility for multiple therapeutic franchises. Several discovery programs are underway to advance Syncrovax through clinical development. The company’s mission is to be the world leader in optimized intratumoral immuno-oncology drug development and therapies. Syncromune is headquartered in Fort Lauderdale, FL, USA. For more information, please visit www.syncromune.com.
The Syncrovax platform is being developed to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. Syncrovax utilizes a combination approach of tumor lysis and intratumoral immunotherapy delivery. The treatment is intended to change the tumor microenvironment from immunosuppressive to immunostimulatory by activating the innate and adaptive immune responses and potentially increasing T cell functions. The immune responses triggered are intended to enable an anti-cancer response that is expected to act at the site of the treated tumor as well as in metastases throughout the body.
This press release includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this press release or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as “plans,” “intends,” “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this press release or expressed orally in connection herewith are made only as of the date of this press release and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this press release; or (ii) the accuracy or completeness of any information contained in this press release, any other written information or oral information provided in connection herewith or any data that any of them generates. This press release was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune’s securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Some of the information contained in this press release may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.
Chief Financial Officer
View the conference schedule HERE
Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd. https://t.co/617YOehYqkRead More
RT @CancerResearch: June kicks off Cancer Immunotherapy Month™. Let's fuel the next scientific discoveries and breakthrough treatments thro…Read More
Mathematical method developed to predict cancer and drug-specific immunotherapy efficacy via @medical_xpressRead More
New clues to prostate cancer: Why aggressive subtype can resist treatment via @medical_xpressRead More
The information contained in our press releases and presentations should be considered accurate only as of the date it was originally issued. Syncromune™ disavows any obligation to update the information contained in these press releases and presentations after the date of their issuance.